Icon Plc (ICLR) Holdings Reduced by Hillsdale Investment Management Inc.
Hillsdale Investment Management Inc. cut its position in Icon Plc (NASDAQ:ICLR) by 39.5% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,800 shares of the medical research company’s stock after selling 1,830 shares during the period. Hillsdale Investment Management Inc.’s holdings in Icon Plc were worth $274,000 as of its most recent SEC filing.
A number of other large investors have also recently added to or reduced their stakes in the business. Renaissance Technologies LLC increased its holdings in shares of Icon Plc by 252.6% during the first quarter. Renaissance Technologies LLC now owns 955,860 shares of the medical research company’s stock worth $76,201,000 after buying an additional 684,760 shares in the last quarter. FMR LLC raised its stake in shares of Icon Plc by 38.4% in the second quarter. FMR LLC now owns 2,291,005 shares of the medical research company’s stock valued at $224,037,000 after acquiring an additional 635,950 shares during the last quarter. Clearbridge Investments LLC raised its stake in shares of Icon Plc by 45.2% in the first quarter. Clearbridge Investments LLC now owns 1,594,656 shares of the medical research company’s stock valued at $127,126,000 after acquiring an additional 496,700 shares during the last quarter. Mckinley Capital Management LLC Delaware raised its stake in shares of Icon Plc by 2,674.8% in the second quarter. Mckinley Capital Management LLC Delaware now owns 338,520 shares of the medical research company’s stock valued at $33,104,000 after acquiring an additional 326,320 shares during the last quarter. Finally, WCM Investment Management CA raised its stake in shares of Icon Plc by 6.8% in the second quarter. WCM Investment Management CA now owns 3,965,106 shares of the medical research company’s stock valued at $387,747,000 after acquiring an additional 252,853 shares during the last quarter. Hedge funds and other institutional investors own 91.53% of the company’s stock.
Several research analysts have recently commented on ICLR shares. Jefferies Group LLC raised Icon Plc from a “hold” rating to a “buy” rating and boosted their target price for the stock from $86.00 to $117.00 in a report on Thursday, June 29th. Zacks Investment Research raised Icon Plc from a “hold” rating to a “buy” rating and set a $108.00 price target for the company in a report on Tuesday, June 27th. BidaskClub upgraded Icon Plc from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. SunTrust Banks, Inc. upgraded Icon Plc from a “hold” rating to a “buy” rating and lifted their price objective for the company from $93.00 to $126.00 in a research report on Monday, July 31st. Finally, Credit Suisse Group reissued a “buy” rating on shares of Icon Plc in a research note on Friday, July 28th. Three research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $113.00.
Icon Plc (NASDAQ ICLR) opened at 113.88 on Monday. The company has a market capitalization of $6.15 billion, a price-to-earnings ratio of 23.10 and a beta of 0.59. The firm has a 50-day moving average price of $108.70 and a 200-day moving average price of $93.99. Icon Plc has a 12 month low of $73.76 and a 12 month high of $117.53.
Icon Plc (NASDAQ:ICLR) last announced its quarterly earnings results on Thursday, July 27th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.30 by $0.01. Icon Plc had a net margin of 15.97% and a return on equity of 28.72%. The company had revenue of $431.00 million during the quarter, compared to the consensus estimate of $430.68 million. During the same period in the prior year, the business earned $1.14 earnings per share. The company’s revenue for the quarter was up 5.0% compared to the same quarter last year. On average, equities analysts anticipate that Icon Plc will post $5.32 earnings per share for the current fiscal year.
Icon Plc Company Profile
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Icon Plc (NASDAQ:ICLR).
Receive News & Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related companies with Analyst Ratings Network's FREE daily email newsletter.